5U68

Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.083 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.184 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.

Wen, X.Mousa, J.J.Bates, J.T.Lamb, R.A.Crowe, J.E.Jardetzky, T.S.

(2017) Nat Microbiol 2: 16272-16272

  • DOI: 10.1038/nmicrobiol.2016.272

  • PubMed Abstract: 
  • Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly <sup>1 </sup>, with a significant health burden <sup>2-6 </sup>. There are no license ...

    Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly 1 , with a significant health burden 2-6 . There are no licensed vaccines or small-molecule antiviral treatments specific to these two viruses at present. A humanized murine monoclonal antibody (palivizumab) is approved to treat high-risk infants for RSV infection 7,8 , but other treatments, as well as vaccines, for both viruses are still in development. Recent epidemiological modelling suggests that cross-immunity between RSV, HMPV and human parainfluenzaviruses may contribute to their periodic outbreaks 9 , suggesting that a deeper understanding of host immunity to these viruses may lead to enhanced strategies for their control. Cross-reactive neutralizing antibodies to the RSV and HMPV fusion (F) proteins have been identified 10,11 . Here, we examine the structural basis for cross-reactive antibody binding to RSV and HMPV F protein by two related, independently isolated antibodies, MPE8 and 25P13. We solved the structure of the MPE8 antibody bound to RSV F protein and identified the 25P13 antibody from an independent blood donor. Our results indicate that both antibodies use germline residues to interact with a conserved surface on F protein that could guide the emergence of cross-reactivity. The induction of similar cross-reactive neutralizing antibodies using structural vaccinology approaches could enhance intrinsic cross-immunity to these paramyxoviruses and approaches to controlling recurring outbreaks.


    Organizational Affiliation

    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.,Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.,Vanderbilt Vaccine Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.,Department of Structural Biology, Stanford University School of Medicine, Stanford, California 94305, USA.,Howard Hughes Medical Institute, Northwestern University, Evanston, Illinois 60208-3500, USA.,Department of Molecular Biosciences, Northwestern University, Evanston, Illinois 60208-3500, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Chimera protein of Fusion glycoprotein F0 and Envelope glycoprotein
A, B, C
562Human immunodeficiency virus 1Human respiratory syncytial virus A (strain A2)
This entity is chimeric
Mutation(s): 0 
Gene Names: F
Find proteins for M1E1E4 (Human immunodeficiency virus 1)
Go to UniProtKB:  M1E1E4
Find proteins for P03420 (Human respiratory syncytial virus A (strain A2))
Go to UniProtKB:  P03420
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
MPE8
E, F, G
294N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.083 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.184 
  • Space Group: P 31 2 1
Unit Cell:
Length (Å)Angle (°)
a = 155.540α = 90.00
b = 155.540β = 90.00
c = 275.930γ = 120.00
Software Package:
Software NamePurpose
XDSdata scaling
PHASERphasing
PHENIXrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesGM-61050

Revision History 

  • Version 1.0: 2017-02-15
    Type: Initial release
  • Version 1.1: 2017-03-22
    Type: Source and taxonomy
  • Version 1.2: 2017-08-09
    Type: Database references
  • Version 1.3: 2017-09-27
    Type: Author supporting evidence